South Dakota Investment Council Boosts Stake in Moderna, Inc. (NASDAQ:MRNA)

South Dakota Investment Council grew its stake in shares of Moderna, Inc. (NASDAQ:MRNA) by 4.0% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 299,399 shares of the company’s stock after buying an additional 11,500 shares during the quarter. South Dakota Investment Council owned 0.08% of Moderna worth $12,449,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently made changes to their positions in the business. State Street Corp grew its holdings in shares of Moderna by 12.1% during the 3rd quarter. State Street Corp now owns 16,847,212 shares of the company’s stock valued at $1,125,899,000 after purchasing an additional 1,823,276 shares during the last quarter. Geode Capital Management LLC grew its holdings in shares of Moderna by 2.6% during the 3rd quarter. Geode Capital Management LLC now owns 7,069,580 shares of the company’s stock valued at $470,670,000 after purchasing an additional 178,115 shares during the last quarter. Wellington Management Group LLP grew its holdings in shares of Moderna by 21.0% during the 3rd quarter. Wellington Management Group LLP now owns 5,224,685 shares of the company’s stock valued at $349,166,000 after purchasing an additional 906,114 shares during the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its holdings in shares of Moderna by 0.5% during the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 3,890,812 shares of the company’s stock valued at $260,023,000 after purchasing an additional 19,819 shares during the last quarter. Finally, The Manufacturers Life Insurance Company grew its holdings in shares of Moderna by 6.2% during the 3rd quarter. The Manufacturers Life Insurance Company now owns 3,073,934 shares of the company’s stock valued at $205,431,000 after purchasing an additional 178,939 shares during the last quarter. Institutional investors own 75.33% of the company’s stock.

Insider Transactions at Moderna

In other news, insider Shannon Thyme Klinger sold 1,418 shares of Moderna stock in a transaction that occurred on Friday, November 29th. The shares were sold at an average price of $42.79, for a total value of $60,676.22. Following the completion of the sale, the insider now directly owns 19,717 shares in the company, valued at $843,690.43. The trade was a 6.71 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Insiders sold 2,664 shares of company stock worth $115,210 over the last three months. 15.70% of the stock is currently owned by company insiders.

Analyst Ratings Changes

Several equities analysts recently commented on MRNA shares. Morgan Stanley reduced their target price on shares of Moderna from $70.00 to $38.00 and set an “equal weight” rating on the stock in a report on Wednesday, January 15th. Needham & Company LLC reissued a “hold” rating on shares of Moderna in a report on Friday, November 8th. JPMorgan Chase & Co. set a $45.00 price target on shares of Moderna in a report on Friday, February 14th. Bank of America cut their price target on shares of Moderna from $41.00 to $34.00 and set an “underperform” rating on the stock in a report on Tuesday, February 11th. Finally, Berenberg Bank raised their price target on shares of Moderna from $33.00 to $42.00 and gave the stock a “hold” rating in a report on Thursday, January 16th. Four research analysts have rated the stock with a sell rating, fifteen have issued a hold rating, three have assigned a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and an average target price of $60.63.

Moderna Stock Up 5.3 %

Shares of MRNA stock opened at $35.53 on Friday. The company has a 50 day moving average price of $38.04 and a 200-day moving average price of $52.66. Moderna, Inc. has a 52 week low of $29.25 and a 52 week high of $170.47. The firm has a market capitalization of $13.67 billion, a PE ratio of -3.83 and a beta of 1.59.

Moderna Company Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.